공고 • Jun 19
Apontis Pharma AG, Annual General Meeting, Jul 29, 2025 Apontis Pharma AG, Annual General Meeting, Jul 29, 2025, at 10:00 W. Europe Standard Time. 공고 • Nov 21
Shares of Apontis Pharma to Delist Following the Tender Offer Zentiva said on November 19, 2024 that it has lifted the minimum acceptance threshold of 65% in its tender offer to acquire Germany's Apontis Pharma AG. Zentiva launched the offer in October, proposing EUR 10 per share. The planned deal values Apontis Pharma at EUR 85 million. Following the tender offer, Apontis Pharma shares will no longer be traded on the open market. A separate delisting bid will not be required, Zentiva said. 공고 • Oct 24
Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH). Zentiva AG initiated a tender offer to acquire 62.50% stake in Apontis Pharma AG (XTRA:APPH) on October 24, 2024. A cash consideration valued at €10 per share will be paid by Zentiva AG. As part of consideration, an undisclosed value is paid towards common equity of Apontis Pharma AG. Through a German unit, Zentiva is offering €10 per share, which represents a premium of 52.9% over the closing price on October 15, or a day before the transaction was first announced. Apontis management and supervisory boards welcome the offer and plan to recommend shareholders to accept it. The Offer values APONTIS PHARMA at €85 million for 100% of share capital. Both the Management Board and the Supervisory Board of APONTIS PHARMA welcome the Offer. Subject to review of the Offer Document and in compliance with their fiduciary duties, both the Management Board and the Supervisory Board intend to support the Offer and to recommend all APONTIS PHARMA shareholders to accept the Offer. They have already confirmed that they will tender any APONTIS PHARMA shares held by them into the Offer. Zentiva and Paragon, the main shareholder of APONTIS PHARMA, have entered into a share sale and purchase agreement with respect to its stake of approx. 37.5% of APONTIS PHARMA shares at a cash consideration in the amount of EUR 9.00 per share, emphasizing the attractiveness of the offer price. Settlement of the Offer will be subject to customary offer conditions, including regulatory clearances. It also includes a minimum acceptance threshold of 65% of APONTIS PHARMA shares. The transaction is expected to close at the end of Q4 2024 or in Q1 2025. Reported Earnings • Mar 29
Full year 2023 earnings released Full year 2023 results: Revenue: €38.7m (down 31% from FY 2022). Net loss: €11.3m (down €14.0m from profit in FY 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 5.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. 공고 • Nov 09
Apontis Pharma Provides Earnings Guidance for the Full Year 2023 Apontis Pharma provides earnings guidance for the full year 2023. The company expects sales of EUR 36.1 million. 공고 • Jul 29
Apontis Pharma AG to Report First Half, 2023 Results on Aug 10, 2023 Apontis Pharma AG announced that they will report first half, 2023 results on Aug 10, 2023 공고 • Jun 29
Aontis Pharma AG Launches Single Pill Finder and Distribution of Single Pill Rosazimib APONTIS PHARMA AG launched Single Pill Finder and distribution of Single Pill Rosazimib - First of three launches in 2023. Single Pill Finder online application shows real-time options to simplify therapy. Free-of-charge physician assistance system for convenient continuation of loose combination as Single Pill. New Single Pill Rosazimib on the market. Further Single Pills to be marketed in 2023. Single Pills combine the established active ingredients in a single tablet in a daily single dose compared to loose combination therapy. The reduced number of tablets can increase adherence and thus contribute to improving prognosis, as demonstrated in the retrospective START and START 2.0 studies and the prospective SECURE study, among others. In addition, the new Single Pill Rosazimib is now available on the market, bringing the portfolio of already approved products in Germany to 11 Single Pills. As an online physician assistance system, the free-of-charge Single Pill Finder shows possible Single Pill options for simplifying therapy for patients on polymedication. Based on the existing nationally standardized medication plan for loose combination preparations, the physician receives real-time recommendations for substitution with Single Pills. The medication plan can be entered in manually, as a photo or uploaded as a scan via desktop, tablet, or smartphone. The results are presented in a smart sort order according to the degree to which the therapy can be simplified, e.g., the portion of single tablet substitutions. This makes it much easier for physicians to access solutions for simplifying therapies. The development for use under practice conditions was carried out with the participation of more than 400 physicians in Germany, according to the motto " by physicians for physicians". Launch of new Single Pill RosazIMib (AP - D01) continues APONTIS PHARMA's announced Single Pill portfolio expansion, providing substitution therapy for the loose combination of Rosuvastatin and Ezetimibe. Launched on 28 June 2023, indications include primaryhypercholesterolemia/homozygous familial hypercholesterolemia (HoFH) and prevention of cardiovascular events in patients with a history of coronary artery disease (CAD) and acute coronary syndrome. Valuation Update With 7 Day Price Move • May 03
Investor sentiment deteriorates as stock falls 41% After last week's 41% share price decline to €7.00, the stock trades at a forward P/E ratio of 100x. Average forward P/E is 15x in the Pharmaceuticals industry in the United Kingdom. Reported Earnings • Apr 02
Full year 2022 earnings released Full year 2022 results: Revenue: €58.4m (up 14% from FY 2021). Net income: €2.69m (up €3.43m from FY 2021). Profit margin: 4.6% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Pharmaceuticals industry in the United Kingdom. Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment deteriorated over the past week After last week's 19% share price decline to €7.95, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 14x in the Pharmaceuticals industry in the United Kingdom. Valuation Update With 7 Day Price Move • Nov 30
Investor sentiment improved over the past week After last week's 23% share price gain to €9.82, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 13x in the Pharmaceuticals industry in the United Kingdom. 
